Increased expression of the astrocytic intermediate filament protein GFAP is a characteristic of astrogliosis. This process occurs in the brain during aging and neurodegeneration and coincides with impairment of the ubiquitin proteasome system. Inhibition of the proteasome impairs protein degradation; therefore we hypothesized that the increase in GFAP may be the result of impaired proteasomal activity in astrocytes. We investigated the effect of proteasome inhibitors on GFAP expression and other intermediate filament proteins in human astrocytoma cells and in a rat brain model for astrogliosis. Extensive Quantitative RT-PCR, immunocytochemistry and western blot analysis resulted unexpectedly in a strong decrease of GFAP mRNA to less than 4% of control levels (Control (DMSO) 100±19.2%; Proteasome inhibitor (Epoxomicin) 3.5±1.3%, n=8, p<0.001) and a loss of GFAP protein in astrocytes in vitro. We show that the proteasome alters GFAP promoter activity, possibly mediated by transcription factors as demonstrated by a GFAP promoter-luciferase assay and RT 2 Profiler PCR array for human transcription factors. Most importantly, we demonstrate that proteasome inhibitors also reduce GFAP and vimentin expression in a rat model for induced astrogliosis, in vivo. Therefore, proteasome inhibitors could serve as a potential therapy to modulate astrogliosis associated with CNS injuries and disease.
Introduction
Increased expression of the intermediate filaments (IFs) glial fibrillary acidic protein (GFAP) and vimentin and the re-expression of nestin are the hallmarks of astrogliosis. This process occurs in the aging brain and is also induced by neurodegenerative processes present in diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) (Cotrina and Nedergaard, 2002 ) and Alexander's disease (AxD) (Borrett and Becker, 1985; Duckett et al., 1992) . GFAP is the major IF protein in mature astrocytes and forms an important part of the astrocyte's IF cytoskeleton. Multiple isoforms of GFAP are expressed in the human brain (Nielsen et al., 2002; Hol et al., 2003; Roelofs et al., 2005; Blechingberg et al., 2007) , of which the canonical form is GFAPα. Both protein and mRNA levels of GFAP have been shown to increase with age (Goss et al., 1991; Nichols et al., 1993) and neurodegeneration (Porchet et al., 2003; Ingelsson et al., 2004) .
Next to an increase in GFAP levels, it has also been shown that the ubiquitin proteasome system (UPS) is impaired in the aged brain and in AD (Keller et al., 2000; de Vrij et al., 2004) , PD (Olanow and McNaught, 2006) and AxD (Keller et al., 2009 ). The UPS is the principal cellular protein degradation system that tags and targets short-lived proteins, for instance transcription factors, as well as aberrant proteins, such as incomplete, missense and misfolded proteins, for destruction (Goldberg, 2003) . The UPS modulates many regulatory proteins that control cellular processes such as inflammatory response, cell cycle, cell growth, signal transduction and cellular differentiation (Ciechanover, 1994; Hershko and Ciechanover, 1998) . The UPS is present in all living cells in both the cytoplasm and the nucleus and has been identified in almost every species from Archaebacterium to human. The proteasome is a multi-catalytic protease that comprises a 20S core and a 19S lid. The ubiquitinated target protein is unfolded and fed into the core of the proteasome, where the protein is degraded by the three different enzymatic activities: trypsin-like, chymotrypsinlike and PGPH-like (Pickart and Cohen, 2004) .
It is generally presumed that the accumulation of non-degraded proteins resulting from inhibition of the proteasome will affect cellular homeostasis. However, proteasomal inhibition may also affect cellular processes via other mechanisms than protein accumulation. 1) It has been suggested that there is a direct link between proteasome inhibition and protein synthesis (Jiang and Wek, 2005; Ding et al., 2006) , resulting in either induced or impaired protein synthesis. Indeed, aging (Rattan, 1996) and some diseases, e.g. AD (Ding et al., 2005) , are associated with a decreased proteasome activity and by a decreased ribosome function and protein synthesis 2) The proteasome has been implicated in controlling expression at the level of transcription (Fleming et al., 2002; Dembla-Rajpal et al., 2004; Auld et al., 2006) . Regulation of gene transcription is a complex interplay between transcriptional regulators, general transcription factors and chromatin structures, which can all be influenced by the UPS, more specifically through modulation of DNA binding and through the proteolysis of transcription factors (Lipford and Deshaies, 2003; Muratani and Tansey, 2003) . 3) Furthermore, recent studies have suggested that the UPS links histone modifications to transcriptional activation (Ezhkova and Tansey, 2004; Lee et al., 2005) . So far, most evidence has been obtained in yeast, and the relevance of the UPS in the regulation of transcription in mammalian cells is mainly inferred from these studies.
In many pathological situations, proteasome activity is impaired. Since astrogliosis and proteasome inhibition often occur mutually in disease conditions, we hypothesized that an impaired proteasomal activity in astrocytes contributes to the increase in IFs such as GFAP. A first indication came from work on AxD, which is caused by missense mutations in GFAP (Li and Zuo, 2005) . It has been suggested that proteasome inhibition can be both a possible cause as well as a consequence of the mutant GFAP accumulation (Tang et al., 2006) in this disease. In the current study we investigated the effect of proteasome inhibition on GFAP expression in human astrocytoma cells and in a rat brain model for astrogliosis. In contrast to our expectation, the data showed that inhibition of the proteasome results in a decrease of GFAP protein levels in astrocytes in vitro and in the rat brain in vivo. We provide evidence that inhibition of proteasome activity directly reduces GFAP transcription thus leading to a rapid decline in GFAP gene expression. Our studies also show that astrogliosis as a result of invasive brain damage can be prevented by a treatment with proteasome inhibitors.
Materials and Methods

Cell lines and inhibitors
Human glioblastoma cell line U343 was a gift from Dr James T. Rutka (Toronto, Canada) and the U251 and SNB19 glioblastoma were a gift from Dr. B. de Leeuw (Erasmus MC Rotterdam, The Netherlands). These cell lines were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM) with Ham F10 (1:1), supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin (all Invitrogen-Life Technologies) at 37ºC with 5% CO 2. The human cervical epithelial carcinoma cell line HeLa and the neuroblastoma cell line SH-SY5Y were cultured in high-glucose DMEM, supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin, at 37ºC with 5% CO 2 . HeLa and SH-SY5Y cells stably expressing the proteasome reporter construct Ub G76V -GFP (Dantuma et al., 2000; Lindsten et al., 2002) were cultured similarly. These GFP-reporter cells lines were selected in the presence of geneticin (Sigma-Aldrich; 0.3mg/ml for HeLa, 0.2mg/ml for SY5Y) and screened for GFP fluorescence upon administration of proteasome inhibitors. Cells were treated with four different proteasome inhibitors: two irreversible inhibitors epoxomicin (Biomol) and lactacystin (Sigma) and two reversible inhibitors MG132 (Affinity Research) and MG262 (Boston Biochem). To verify proteasome-specificity, inhibitors of other proteolytic activities were used: chloroquine (Sigma) to inhibit lysosomal degradation, bacitracin (Sigma) to interfere with the insulin degrading enzyme and Ala-Ala-Phe-chloromethylketone (AAF-cmk, Bachem) to inhibit tripeptidyl peptidase II (TPPII). All chemical inhibitors were dissolved in dimethyl sulfoxide (DMSO), except for chloroquine, which was dissolved in water.
Flow cytometry GFP fluorescence was determined by flow cytometric analysis. Three days prior to the analysis, SH-SY5Y cells and HeLa cells, both stably expressing the Ub G76V -GFP reporter, were cultured in 6-well plates. The cells were treated with proteasome inhibitor one day before flow cytometric analysis was performed. Cell suspensions were fixed in 4% formalin in phosphate buffered saline (PBS; 137mM NaCl, 2.7mM KCl, 1.8mM KH 2 PO 4 , and 4mM Na 2 HPO 4 , pH 7.4) and resuspended in PBS-0.5% bovine serum albumin (Roche). GFP could be directly visualized. Analysis was performed on at least 20,000 cells per sample with a flow cytometer (FACSCalibur, Becton Dickinson Biosciences) and data was analyzed using CellQuest software (BD CellQuest Pro, version 5.2).
Profiling proteasome activity with fluorescent probe
To confirm proteasome inhibition in U343 cells after treatment with various inhibitors and at different concentrations we used a close analog of the bodipyFL fluorescent proteasome activity probe (Berkers et al., 2007) that has identical spectral characteristics. In order to assess the proteasome activity, cells cultured on coverslips were washed in DMEM:Ham F10 medium (1:1, without serum and antibiotics) before incubating the cells with the fluorescent proteasome probe (500nM) in the medium for 3 hours at 37ºC. After that, the cells were rinsed in medium and incubated in the same medium for another hour at 37ºC. Finally, the cells were washed with PBS, fixed in 4% paraformaldehyde (PFA) and washed again with PBS. The coverslips were embedded with Vectashield with DAPI (Vector) and inspected by fluorescence microscopy (Leica DMRE). Probe fluorescence was visualized with FITC filter settings. Images were recorded by a digital camera using fixed exposure settings. Quantification was performed using the ImageJ (NIH) program by outlining the cellular circumference and obtaining the average density value.
Plasmids and transfections
To demonstrate that the proteasome in U343 cells was inhibited after overnight treatment with 100nM epoxomicin, cells were transfected with Ub G76V -GFP, a reporter for proteasome activity which was developed by Dantuma (Dantuma et al., 2000) and has been shown to be stabilized upon proteasome inhibition (Lindsten et al., 2002; van Tijn et al., 2007) . The pGfa2-luciferase reporter gene construct was kindly provided by Michael Brenner (University of Alabama at Birmingham, Birmingham, AL, USA), and was made by cloning the gfa2 promoter from pGfa2-CAT (formerly called pGfaCAT-2 (Besnard et al., 1991) ) in the Bgl II -Hind II sites of Luciferase Reporter Vector pGL3 (Promega). This construct encompasses the human GFAP promoter fused to a luciferase reporter gene, which enables the measurement of GFAP promoter activity. A Renilla luciferase control reporter vector (Promega) was co-transfected as an internal control. Cell culture medium was refreshed 2 hours prior to lipofectamine (Invitrogen) transfection; according to the manufacturer's protocol. For the GFAP-promoter activity measurements, cells were co-transfected with pGfa2-luciferase (0.8μg/per well) and pRL-TK (Renilla) (1ng/per well) in a 24-well plate. Culture medium was refreshed 4 hours after transfection and one day later epoxomicin (final concentration 100nM) or DMSO (final concentration 0.01%) was added to the culture medium for approximately 16 hours.
Cells transfected with Ub
G76V
-GFP were viewed with a fluorescence microscope (Zeiss Axiovert 10) and images were made with a digital camera (Canon Powershot G6) to show accumulation of green fluorescent protein after proteasome inhibition. For luciferase measurements, the cells were rinsed with PBS and lysed in 100 μl reporter lysis buffer (Promega) on a rocking table for 15 min at room temperature (RT). The cell lysate was transferred to a tube and centrifuged for 30 sec at 20,000 x g. The supernatant was collected in a new tube and stored at -80ºC. Per sample, 5 μl was measured for luciferase activity using the luciferase reporter assay system (Promega) and a luminometer (Berthold Technologies).
RNA isolation, reverse transcription and Real-Time Quantitative-PCR (Q-PCR)
For RNA isolation the cells were rinsed in PBS, scraped from the well plate in PBS and centrifuged for 5 min at 1,000 x g. Supernatant was removed and the pellet was stored at -20ºC until RNA was isolated. 1 ml TRIzol Reagent (Invitrogen) was added to the cell pellet. Total RNA was isolated according to the manufacturer's protocol. The resulting RNA pellet was dissolved in distilled water and stored at -80ºC. RNA concentration was determined using a NanoDrop ® ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). Subsequently, 2μg RNA was treated with DNaseI (Invitrogen) and reverse transcribed with Superscript II RT (Invitrogen), according to the manufacturer's protocol, using random hexanucleotides (Roche). The cDNA was stored at -20ºC for later use in Q-PCR reaction. Q-PCR was carried out in 96-well plates, with a final volume of 20 µl per well using the SYBR Green PCR kit (Applied Biosystems). Each reaction volume contained 10µl SYBR Green mix (2x concentrated), 6µl H 2 O, 1µl cDNA sample and 3µl of primer mix (sense and antisense primers, each 2pmol/µl; see supplemental table 1 for primer sequences). The plate was sealed and spun for 1 min at 200 x g before starting the Q-PCR program with the following cycling conditions: 2 min at 50ºC; 10 min at 95ºC; 15 sec at 95ºC, and 1 min at 60ºC for 40 cycles. After the amplification protocol a dissociation curve was constructed by ramping the temperature from 60 to 90 ºC. The resulting Ct values were converted to absolute amounts of cDNA present in the sample (E-Ct) (Dijk et al., 2004) . To correct for differences in cDNA amounts between samples, we normalized the target PCR to the geomean values of PCRs on a set of reference genes. Transcript levels of E2 ubiquitin ligase (E2Ubi), RNA polymerase II (RNA pol II) and 18S ribosomal RNA (18S) were most stable and used for normalization.
MTT cell viability assay
Cells were seeded onto 24-well plates and were treated with proteasome inhibitors or DMSO for the indicated time periods. Subsequently, culture medium was replaced for serum free medium without phenol and 50 μl MTT solution (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, 5 mg/ml in PBS) was added to each well and incubated at 37° for 4 h. After that, medium was removed and 500 μl DMSO was added to each well and incubated for 5-10 min to dissolve the formazan crystals. Two times 50 μl was transferred to a 96-wells plate and absorbance was measured at a wavelength of 570 nm on a microplate reader (Molecular devices).
Immunocytochemistry U343 cells, cultured on gelatin-coated coverslips, were rinsed with PBS and fixed in 4% PFA in PBS. Following fixation the cells were rinsed again with PBS and incubated with Supermix (0.05M Tris, 0.9% NaCl, 0.25% gelatin and 0.5% Triton X-100, pH 7.4) for 10 min at RT. The cells were then incubated with anti-GFAP, -vimentin, -nestin, or -Hsp70 antibodies (see table 1 for details) in Supermix overnight at 4°C. Subsequently, the cells were rinsed with Tris buffered saline (TBS; 100mM Tris-HCl pH 7.4, 150mM NaCl) following incubation with Cy3-or Cy2-labeled secondary antibodies (1:400; Jackson ImmunoResearch Laboratories) in Supermix for 1 h at RT. Finally the cells were rinsed three times with TBS, once with 0.05M Tris and coverslipped in Vectashield with DAPI (Vector Laboratories).
For immunostaining of the rat brain sections, blocking was performed by preincubation with 10% normal serum and 0.4% Triton X-100 in 0.05M phosphate buffer (0.05M Na 2 HPO 4 , 0.05M NaH 2 PO 4 ·H 2 O, pH 7.4) for 1 hour. Subsequently, the sections were incubated with the primary antibody diluted in 0.05M phosphate buffer containing 3% normal serum and 0.4% Triton X-100. Incubations with the primary antibodies against GFAP, vimentin, S100, NeuN and Hsp70 (see table 1 for details) were carried out overnight at RT. Slides were rinsed and incubated with F(ab')2-Cy3 secondary antibodies for 1 hour (Jackson ImmunoResearch Laboratories; 1 μg/ml). Sections were washed and cover-slipped in Vectashield with DAPI (Vector Laboratories). Both the U343 cells and rat brain sections were visualized on a Leica DMRE fluorescence microscope. Digital images were collected of the area around the implanted probes with identical settings for the areas around the perfused probe (experimental -control) and for the area around the contralateral non-perfused probe.
Western blot
Protein was isolated from U343 cells treated with epoxomicin or DMSO by homogenization with lysis buffer (0.1M NaCl, 0.01M Tris-HCl pH 7.6, 1mM EDTA pH 8.0) supplemented with a protease inhibitor cocktail (Roche). Cell lysates were sonicated twice for 10 seconds and centrifuged for 3 min at 20,000 x g. Supernatantand pellet-fraction were collected and dissolved in 2x, or 1x loading buffer (2x: 100mM Tris, 4% SDS, 20% glycerol, 200mM DTT, 0.006% bromophenol blue) respectively and boiled for 5 minutes. Subsequently, they were run on a 7.5% SDS-PAGE gel and blotted semi-dry on nitrocellulose. Blots were probed overnight with polyclonal anti-GFAP (see table 1) in Supermix. The next day, the blots were washed with TBS-T (TBS with 0.2% tween-20) and incubated with secondary antibody anti-Rabbit IRDye800 in Supermix (1:5000; Rockland) for one hour at RT. After three washes in TBS, bands were visualized with the Odyssey Infrared Imaging System (LI-COR Biosciences). Quantification of GFAP protein levels was performed using Odyssey Software version 2.1 by measuring the integrated intensity with subtracted background of GFAP protein bands. These integrated intensities were divided by the total amount of protein in the samples, which was either measured with a Bradford assay (soluble protein) or by Coomassie gel quantification (insoluble protein). Protein percentages were calculated of epoxomicin treated cells compared to the DMSO control.
Statistical analysis
To demonstrate whether statistically significant differences existed among different groups, the non-parametric Kruskal-Wallis test was used. For all target genes in the Q-PCR studies, the statistical analysis was performed on the normalized values.
RT array
Two plates of the RT 2 Profiler PCR array for human transcription factors (PAHS-075 A; SuperArray, Frederick, USA) were used comparing Q-PCR validated cDNA samples of an overnight 100nM treatment with epoxomicin and a vehicle control. cDNA equivalent to 1 ug total RNA was used for each plate. The cDNA was mixed with the RT 2 SYBR Green/ROX Q-PCR master mix and 25ul was added to each of the wells containing different primers. The plate was run under the same conditions as described above. The outcome was normalized against the set of reference genes used for the Q-PCR. Analysis using the references genes present on the array yielded a comparable outcome.
In-Silico Analyses
We used the Genomatix Software (www.genomatix.de). The RefSeqs of GFAP, Vimentin and Nestin (human) were used as input for the MatInspector, Gene2Promoter and FrameWorker tools searching for promoter regions in individual transcripts and for promoter regions common to the three genes (Cartharius et al., 2005) . The target sequence of GFAP was adjusted to 2163 bp upstream and 47 bp downstream of transcriptional start sites reflecting the promoter sequence of pGfa2-luc.
Animals and surgery
Experimentally naive male Wistar rats (Harlan/CPB-WU, bodyweight of 250-350 grams at time of the experiment) were kept in a temperature and humidity controlled room. Animals were housed in macrolon cages with sawdust bedding and ad libitum food and water. Microdialysis probes were placed bilaterally in the prefrontal cortex (PFC) at an angle of 12º as previously described in detail (van der Meulen et al., 2007) or in the striatum at an angle of 0º (coordinates in mm from Bregma: A +1.0, L +2.5, V -6,.0). The exposed membrane length of the Hospal AN69 dialysis membrane (outer diameter 0.32mm in watery medium) was 4mm for the PFC and 3mm for the striatum. After surgery, a subcutaneous injection of 0.075 mg/ kg buprenorfine (Temgesic®, Schering-Plough, Reckitt Benckiser, UK) was given and rats were housed separately.
Microdialysis
Microdialysis was started <7 days (n=10) or >7 days (n=4) after probe implantation. Only one of the two implanted probes was connected to Tsumura (TCS 2-23) quartzlined dual channel swivel (Pronexus, Skärholmen, Sweden) and to a perfusion pump using flexible PEEK (Upchurch Scientific) and all connections were made using small pieces of PVC tubing (inner diameter 0.38mm; Watson-Marlow). Prior to the experimental perfusions, the probes were perfused for 2 days with Ringer (145mM NaCl, 2.7mM KCl, 1.2mM CaCl 2 , and 1mM MgCl 2 ). For the experimental procedure, the perfused Ringer contained either 0.025% DMSO or 250nM epoxomicin-0.025% DMSO. Solutions were perfused at a rate of 2μl/min and when the flow of the first probe was found to be obstructed when attempting to start the microdialysis, the second probe was used. Animals were perfused continuously for 72 h. The flow from the outlet was collected to monitor whether the flow was uninterrupted. Animals did not show changes in their overall behaviour during perfusion.
Tissue processing
After 72 h perfusion the animals were disconnected from the microdialysis system. Animals were anesthetized by an intra-peritoneal injection with 1.0 ml Nembutal and transcardially perfused with 150 ml PBS followed by 500 ml freshly prepared 4% PFA in PBS at pH 7.2. After perfusion the dental acrylic head mount including the microdialysis probes was pulled away from the skull. The brain was isolated and a 5mm thick coronal slice was cut around the area with the probe position. The slice was cryoprotected overnight in PBS containing 15% sucrose, frozen on powdered dry ice, and stored at -80 °C until sectioning. Serial 10μm cryosections were cut and thaw-mounted on SuperFrost Plus slides. Sections were dried for 1 h and stored at -20°C. Immunocytochemistry was performed as described above.
Results
The intermediate filaments GFAP, vimentin and nestin are expressed in U343 cells
To investigate whether the U343 astrocytoma cell line is useful to study the effect of proteasome inhibition on GFAP and other IF proteins, the expression of IF proteins involved in astrogliosis was analyzed in these cells. Fluorescent staining clearly showed GFAP-, vimentin and nestin immunoreactivity (IR) in all U343 cells ( Figure 1 ). Although it was reported previously that U343 cells do not express nestin (Rutka et al., 1999) , nestin positive cytoskeletal filaments were evident in this study, similar to GFAP-and vimentin positive filaments. Moreover, Q-PCR showed the presence of nestin transcripts ( Figure 4D ).
Inhibition of the proteasome by epoxomicin
The optimal concentration of proteasome inhibitor epoxomicin needed to inhibit the activity of the proteasome was determined in HeLa and SH-SY5Y cell lines stably transfected with Ub G76V -GFP, a reporter for proteasomal activity. Ub is normally targeted to the proteasome for degradation, but when the proteasome is inhibited, the fusion protein is no longer degraded and the green fluorescent protein accumulates. Flow cytometric analysis of these cell lines treated for 16 hours with various concentrations of epoxomicin, showed that in both cell lines 100nM was sufficient to almost completely inhibit the proteasome activity (Figure 2A) . Besides, this concentration was shown to sufficiently inhibit the proteasome in U343 astrocytoma cells, since all U343 cells transfected with the Ub G76V -GFP proteasome reporter construct (~50% transfection efficiency) accumulated GFP when treated with 100nM epoxomicin (Figure 2B-C) . In addition we used a fluorescent probe (Berkers et al., 2007) , which specifically binds to the active proteolytic sites of the proteasome. The labeling observed after overnight DMSO treatment ( Figure 2D ) was almost completely absent after overnight treatment with 100nM epoxomicin ( Figure 2E ), indicating that the core proteasome proteolytic activity became inactive due to epoxomicin treatment. The absence of probe labeling was not the result of cell death, as indicated with an MTT assay ( Figure 5C ). 
Proteasome inhibition in U343 cells resulted in a strong reduction of GFAP mRNA
Next we determined the effect of proteasome inhibition on GFAP protein levels. The U343 cells were treated overnight with 100nM epoxomicin or 0.01% DMSO as control and were immunostained for GFAP. No clear change in GFAP-IR (IR) was observed between DMSO and epoxomicin treated cells ( Figure 3A-B) . At larger magnification a clear filamentous network was visible throughout the cytosplasm in the DMSO treated cells ( Figure 3C ). In the 100nM epoxomicin treated cells this was also seen in many cells ( Figure 3D ) although the GFAP network often appeared less pronounced ( Figure 3E ). We quantified the changes in GFAP protein levels using Western blot. It is known that the turnover of filament proteins such as GFAP shows a biphasic decay, including a fast-decaying pool with a half-life of 12-18 hours and a slow-decaying pool exhibiting a half-life of about 8 days (Chiu and Goldman, 1984) . Most likely, this fast-decaying pool contains the soluble forms of these proteins, while the slow-decaying pool consists of the filamentous, insoluble forms. To distinguish between these two assembly states, a soluble supernatant fraction and an insoluble pellet fraction were loaded onto the gel. Quantification of these Western blots, of which an example is presented in Figure 3F , showed a slight decrease in relative GFAP protein levels in the soluble fraction ( Figure 3G , white bars), which was significant for 5nM (75%, p<0.047), 25nM (56%, p<0.037) and 100nM epoxomicin (63%, p<0.028). No significant changes were found in the insoluble fraction after 16 hours ( Figure 3G , grey bars), which was in line with our expectations, considering the long half-life of insoluble filamentous IF proteins. The relative proteasome activity in U343 cells treated with the concentrations of epoxomicin used in the Western blot experiment was quantified using the fluorescent proteasome activity probe ( Figure 3H ), which confirmed that proteasome activity gradually decreased with increasing concentrations. Because proteasomal activity is involved in the regulation of gene expression (Fleming et al., 2002; Dembla-Rajpal et al., 2004; Auld et al., 2006) , we studied the effect of epoxomicin on GFAP mRNA levels. Relative amounts of GFAP mRNA were measured with quantitative RT-PCR after overnight treatment with 100nM epoxomicin. Remarkably, GFAP transcript levels were profoundly decreased after proteasome inhibition down to less than 5% of the levels in the control condition ( Figure 3I , p<0.001). For comparison, transcript levels of several reference genes that are not related to IFs were measured in the same samples ( Figure 3J ). Epoxomicin treatment had no effect on the expression level of E2Ubi, RNA pol II and 18S, although elongation factor 1α (EF1α) was significantly upregulated (p<0.02). These results indicate that either GFAP mRNA stability or GFAP gene expression is strongly regulated by proteasome activity.
To investigate whether the effect of proteasome inhibition on the GFAP mRNA levels is caused by a direct regulation of the GFAP promoter, U343 cells were transfected with a construct driving the luciferase gene under the human GFAP promoter (pGfa2-luc). Renilla-luciferase was used as an internal control, since proteasome inhibition is known to decrease the activity of luciferase in general (Deroo and Archer, 2002) . The luciferase activity measured from pGfa2-luc after normalization with the Renilla-luciferase was significantly decreased by proteasome inhibition (Figure 3K, p<0.008 ). This result showed that the GFAP promoter after proteasome inhibition exhibits less than a third of its activity compared to the control condition. All together, these data strongly indicate that proteasome inhibition results in a rapid decrease in GFAP transcription, as a result of a less active promoter. 
Specificity of GFAP mRNA downregulation
The strong reduction of the GFAP transcript levels was studied in more detail. GFAP mRNA was measured at different time points after epoxomicin treatment and the effect of different concentrations of epoxomicin was studied. The decrease of GFAP mRNA was dependent on the duration of treatment ( Figure 4A ). After 4 hours of 100nM epoxomicin treatment, the GFAP mRNA levels were decreased to 40%, while an overnight (16 hours) treatment resulted in a nearly complete downregulation of GFAP mRNA. Additionally, the GFAP mRNA downregulation was also shown to be epoxomicin concentration dependent ( Figure 4B) . A concentration of 5nM epoxomicin already showed a drop in GFAP mRNA and a significant decrease in GFAP mRNA levels was reached when concentrations of 10nM epoxomicin (p<0.021) or higher were applied for 16 hours. GFAP mRNA levels were decreased down to approximately 5% of control levels with 25nM (p<0.019) and 100nM (p<0.021) epoxomicin.
Multiple splice variants are derived from the GFAP gene (Quinlan et al., 2007) , i.e.
GFAPα, GFAPΔ135, GFAPΔ164, GFAPΔexon6 (Hol et al., 2003) , GFAPδ (Nielsen et al., 2002; Roelofs et al., 2005) and GFAPκ (Blechingberg et al., 2007) . We investigated whether proteasome inhibition altered the GFAP splicing pattern in U343 cells. GFAPδ mRNA and protein were previously shown to be clearly expressed in U343 IF networks (Perng et al., 2008) , the GFAPΔ164/GFAPΔexon6 proteins (recognized by a GFAP +1 antibody) (Hol et al., 2003) however are not expressed (data not shown). The mRNA expression of the GFAP isoforms was investigated after proteasome inhibition. The GFAPΔ164 and GFAPΔexon6 mRNA could not be detected in U343 cells (not shown), which is in accordance with their absence at the protein level. GFAPα, GFAPδ, GFAPκ and GFAPΔ135 mRNA levels were significantly decreased ( Figure  4C ) and the ratio between the different isoforms remained constant (not shown), indicating that overnight epoxomicin treatment did not change GFAP splicing.
Because GFAP is not the only IF protein present in U343 cells, we tested whether other IF transcripts involved in gliosis were also decreased upon proteasome inhibition. Q-PCR revealed a significant decrease of both vimentin, to approximately 43% of the level found in controls and nestin mRNA levels to approximately 13% after overnight epoxomicin treatment ( Figure 4D , p<0.017). This result demonstrates that the proteasomal activity regulates the mRNA levels of all IFs involved in gliosis in U343 cells with the downregulation of GFAP to levels less than 5% being most pronounced. Vimentin is an IF protein which is present in many cell lines. We tested whether vimentin downregulation upon proteasome inhibition was specific for astrocytoma cells or present in other cell lines as well. A Q-PCR for vimentin was performed on HeLa cells ( Figure 4E ) and SH-SY5Y neuroblastoma cells ( Figure  4F ), in which additionally the neuron-specific IF protein neurofilament-H (NFH) was also tested. These experiments showed no significant downregulation of mRNA expression of any of the tested genes, though a small decrease in vimentin mRNA was detected in both cell lines and a significant upregulation of NFH to 244% was measured in the neuroblastoma cells (p<0.05). To exclude that the effect of proteasome inhibition on IF transcription was solely present in U343 astrocytoma cells, a Q-PCR was performed on astrocytoma cell lines U251 and SNB19 ( Figure  4G ). Although the overall GFAP expression level was lower in these cells compared to U343 cells (data not shown), a significant downregulation was found after proteasome inhibition in both astrocytoma cell lines (p<0.021). This indicates that the regulation of IF transcription through proteasome inhibition is astrocyte-specific.
Next we addressed specificity aspects of the observed effect of epoxomicin on GFAP mRNA levels. U343 cells were treated with several other proteasome activity inhibitors ( Figure 4H ) and inhibitors of other proteolytic enzymes ( Figure  4I ). Overnight treatment with lactacystin, MG132 and the boronate analogue of MG132, MG262, all resulted in a clear and significant reduction of GFAP mRNA comparable to the effects observed with epoxomicin. U343 cells were treated with either chloroquine, an inhibitor of lysosomal degradation, bacitracin, an inhibitor of insulin degrading enzyme or AAF-cmk, an inhibitor of TPPII ( Figure 4I ). Chloroquine and AAF-cmk treatment, both showed a significant downregulation of GFAP mRNA to about 33% of control levels (p<0.05), but the reduction was not as profound as that of the proteasome inhibitors (p<0.05). In contrast, treatment with bacitracin resulted in a significant increase of GFAP mRNA to about 760% (p<0.05).
In conclusion, any effect on GFAP mRNA levels found with other proteases is much smaller or opposite from the effect of the proteasome inhibitors.
Epoxomicin is known to be an irreversible inhibitor of the proteasome whereas the inhibitory effect of MG132 is reversible. Cells were treated overnight with either epoxomicin or MG132, after which the culture medium was refreshed with medium without inhibitors. Cells were harvested 24h later and RNA was isolated ( Figure  4J ). The epoxomicin treated cells showed a significant and irreversible decrease in GFAP mRNA expression, while washout of the reversible inhibitor MG132 caused the significantly decreased levels of GFAP mRNA (p<0.046) to recover to levels not different from controls. This result is in agreement with the pharmacological profile of the two inhibitors (Meng et al., 1999; Josefsberg et al., 2000) . Taken together, these results clearly show that proteasome inhibition is involved in the decreased GFAP mRNA expression.
Induced cell death and stress response are not responsible for the decrease in IF mRNA expression
Proteasome inhibition is known to cause an upregulation of heat shock proteins, including Hsp70 (Bush et al., 1997; Kawazoe et al., 1998) and at long-term, to induce cell death (Ding and Keller, 2001) . We studied whether these effects of proteasome inhibition in U343 astrocytoma cells could be responsible for the effect on the GFAP mRNA expression. Cell death after proteasome inhibition can be detected by studying nuclear condensation, a classic feature of apoptosis. In U343 cells treated with 100nM epoxomicin overnight, no evident condensed nuclei were observed with DAPI staining (Figure 5A-B) . To quantify the viability of the cells, an MTT assay was performed after treatment with proteasome inhibitors epoxomicin and lactacystin. No significant reduction of cell viability was observed after an overnight treatment with either proteasome inhibitor ( Figure 5C ).
To investigate whether heat shock proteins were induced, a Q-PCR with Hsp70 specific primers was performed on cDNA samples from previous experiments. As expected, a highly significant upregulation of Hsp70 mRNA levels was found after proteasome inhibition with several proteasome inhibitors ( Figure 5D , p<0.05). We could confirm this effect at the protein level; no Hsp70-IR could be detected in DMSO treated cells in contrast to epoxomicin treated cells ( Figure 5E-F Norm. GFAPα mRNA (%)
Norm. GFAPα mRNA (%)
Norm. GFAPα mRNA (%) was as efficient to reduce the GFAP mRNA expression as epoxomicin ( Figure 4H ). Additionally, a concentration range of lactacystin showed that at a concentration of 10μM, GFAP mRNA levels were substantially decreased and Hsp70 mRNA levels were not increased yet ( Figure 5G) , showing that an increase in Hsp70 transcript levels or more general heat-shock response is not likely to be the cause for the decrease in GFAP transcript levels. Moreover we measured the expression of BiP, an important component of the endoplasmatic reticulum stress response. Although BiP mRNA levels were significantly increased by tunicamycin treatment, no change was found after epoxomicin treatment (data not shown), which indicates that ER stress was not induced. 
Various transcription factors are regulated by the proteasome in U343 cells
The cell culture studies have provided extensive evidence for the specificity of proteasome inhibition on GFAP transcription in U343 astrocytoma cells. Since it has become more evident that the proteasome has a fundamental role in regulating transcription, partly by regulating transcription factor half-life (Auld et al., 2006; Lassot et al., 2007) , we investigated whether proteasome inhibition regulates (astrocytoma) specific transcription factors that could alter IF transcription in these cells.
To study whether proteasome inhibition has a general effect on the levels of transcription factors we used a RT-PCR array to assess the 100nM epoxomicininduced changes in transcript levels of 84 transcription factors implicated in various regulatory pathways. A total of 76 TF could be detected in U343 cells; 20 showed an upregulation of >1.5-fold and 20 showed a downregulation of >1.5-fold (see supplemental table 2 for RT-PCR array results). We validated the changes in expression for several transcription factors of which a relation was known with the proteasome (Zimmermann et al., 2000; Lim et al., 2004; Choi et al., 2007) or involvement in GFAP expression or astrocyte biology (Miyajima et al., 1996; Gadea et al., 2008; Herrmann et al., 2008; Sakurai and Osumi, 2008) . The changes for upregulated ATF3 and c-Jun transcript levels and downregulated PAX6, E2F1 and STAT3 transcript levels were confirmed by Q-PCR on a set of 5 DMSO-treated and 5 epoxomicin-treated samples ( Figure 6A-B) . STAT3 mRNA, which showed a decrease of 1.7-fold in the PCR array, was downregulated in the epoxomicin-treated samples; however this result was not significant. These results suggest that many transcription factors may be involved in the alteration of GFAP-promoter activity.
To more specifically identify which transcription factors can bind the GFAP promoter as well as the vimentin and nestin promoter, we performed an in silico analysis of the promoter regions of GFAP, vimentin and nestin in order to unravel a common transcription binding profile for these three genes (Genomatix Software GmbH). Using the GFAP RefSeq (NM_002055) as target sequence, MatInspector resulted in potential binding sites for 456 transcription factors. Restricting the target input to the promoter region present in the pGfa2-luc revealed 106 potential transcription factors from 58 different transcription factor families. Because proteasome inhibition also reduced the transcript levels of vimentin and nestin, a functional assessment of binding sites was carried out by the Gene2Promoter and FrameWorker tools to find common elements. Gene2Promoter identified 20 transcription factor binding sites that are present in GFAP, vimentin and nestin. Applying the "tissue filter" nervous system reduced this number to binding sites for six transcription factor families: V$CREB (n=14 different transcription factors), V$EGRF (n=7), V$ETSF (n=16), V$NR2F (n=12), V$PARF (n=5), V$PAX6 (n=5).
Altogether, 59 different transcription factors; so even under stringent settings the number of potential candidates remains high and does not allow drawing conclusions as to which transcription factors play a key regulatory role.
Astrogliosis is decreased after proteasome inhibition in vivo
Because filamentous GFAP and other IF proteins have a half-life of approximately 8 days, only longer period of reduced mRNA levels will have substantial effects on the existing IF network. Treatment of U343 cells with high concentrations of proteasome inhibitors for >3 days is toxic to the cells, whereas low concentrations did not lead to an impaired proteasome activity (data not shown). Therefore we studied the effects of chronic proteasome inhibition on GFAP protein levels in a rat model for induced astrogliosis. It is known that in rats the implantation of a microdialysis probe in the hippocampus, causes build up of gliosis in an area around the probe after 24 to 48 hours, reducing the drainage. This layer of GFAP-IR and astrocytic hypertrophy is most prominent after 72 hours, but does not progress after that (Benveniste and Diemer, 1987; Shuaib et al., 1990) . We made use of this model of astrogliosis by perfusing the microdialysis probe, implanted in either the PFC or striatum with epoxomicin. This approach enables the delivery of the proteasome inhibitor precisely at the core of the astrogliosis. Five days after implantation, GFAP positive reactive astrocytes were observed around the control probe that was perfused with 0.025% DMSO in Ringer for 72 hours (result not shown), comparable to the contralateral non-perfused probe ( Figure 7A-B) . In contrast around the probe perfused with 250nM epoxomicin (in DMSO/Ringer) for 72 hours, a clear reduction in GFAP-IR was observed (Figure 7C-D) . Only a few filaments and 'squiggles' (Prahlad et al., 1998) were labeled by the GFAP antibody ( Figure 7C, arrowheads) . The reduction in GFAP-IR was most notably in a zone up to 300μm distant from the probe. Beyond this zone, GFAP positive astrocytes appeared normal, indicating the extent of the epoxomicin diffusion in these conditions. These results show that inhibition of the proteasome can prevent the increase of GFAP levels associated with astrogliosis. To substantiate this, we stained adjacent sections for vimentin, also known to be upregulated in astrogliosis. Vimentin-IR clearly showed a rim of reactive astrocytes around the DMSO and non-perfused probe position ( Figure 7E ), but was virtually absent when the probe was perfused with epoxomicin ( Figure 7F ). In a number of experiments, the start of the probe perfusion with epoxomicin was delayed to >7 days after probe implantation. In these brains, no clear effect on the expression of GFAP or vimentin was observed between the non-and epoxomicin-perfused probe site with either GFAP or vimentin staining (results not shown) suggesting that at this point gliosis had already progressed to a stage where IF gene expression was not susceptible to epoxomicin anymore. To prove that the reduction in GFAP and vimentin-IR is not due to astrocyte cell death, the sections were stained for S100β, another marker for mature astrocytes specific for a family of calcium binding proteins ( Figure 7G-H) . No evident differences were found between the non-perfused and epoxomicin-perfused probe site. S100β-IR was clearly visible in astrocytes around the epoxomicin-perfused probe site, similar to the control site. To show that neurons in the area around the probed were not affected by epoxomicin a NeuN staining was performed. Both around the non-perfused and the epoxomicin-perfused probe a similar number of neurons could be detected ( Figure  7I-J) . Immediately surrounding the probe site, neurons were completely absent in both the epoxomicin-perfused and non-perfused condition ( Figure 7I-J, arrowheads) .
Hsp70-IR which was highly upregulated after epoxomicin treatment in vitro was also greatly enhanced in the epoxomicin-perfused rat brain in all cell types present in that region ( Figure 7L ). Hardly any Hsp70 was detected around the non-perfused probe site ( Figure 7K ), whereas a clear zone of Hsp70-IR cells were visible around the epoxomicin-perfused probe site overlapping with the reduced GFAP-staining. This ring may mark the area of epoxomicin diffusion from the probe into the rat brain. Although heat shock proteins are known to be upregulated at sites of inflammation, no signs of increased inflammation were detected with a CD11b antibody around the epoxomicin-perfused probe site compared to the control site (not shown). These results suggest that proteasome inhibitors in vivo can locally prevent GFAP and vimentin protein accumulation without obvious damage to the surrounding tissue.
Discussion
Astrogliosis and an impaired proteasome activity both occur in the aging brain and in neurodegenerative diseases, such as AD and PD. This has led us to speculate that the UPS might contribute to the regulation of astrogliosis, for instance in the regulation of IF components such as GFAP. In this study we show that in contrast to our expectations, proteasome inhibition does not induce an accumulation of GFAP protein, but rather induces a sharp decrease in the transcript levels of all expressed GFAP isoforms and other cytoplasmic IF protein transcripts in human astrocytoma cells in vitro. In line with these findings, we observed that proteasome inhibition prevents the accumulation of GFAP and vimentin in reactive astrocytes in the rat brain in vivo, thereby suppressing reactive gliosis.
The reduction of GFAP gene expression as a result of proteasome inhibition is highly significant and specific for astrocytes. Biochemically distinct proteasome inhibitors decreased GFAP mRNA levels to less than 5% of the control levels. Several inhibitors of other proteolytic enzymes also affected GFAP transcript levels ( Figure  4H-I non-perfused Epox-perfused * inhibitors. The small but significant downregulation by chloroquine, an inhibitor of lysosomal degradation, could be explained by recent findings from Sprangers et al., who showed in eukaryotic cell extracts and in preparations of purified 20S archaeal proteasomes that chloroquine can inhibit proteasome function as well (Sprangers et al., 2008) . Another explanation could be that lysosomes also regulate factors important for GFAP transcription, but to a lesser extent. The significant effect by TPPII inhibitor AAF-cmk was less unexpected since it is known that TPPII may substitute for some proteasome functions (Geier et al., 1999) . Previous studies in aging rodent and human brains have pointed out that increased GFAP protein could result from either transcriptional or post-transcriptional regulation (Nichols et al., 1993; Yoshida et al., 1996; Riol et al., 1997; Sabbatini et al., 1999) . The results of the pGfa2-luciferase experiment ( Figure 3K ) and the RT-PCR array (supplemental table 2) show that the proteasome alters the transcription of GFAP and other IF proteins most likely by affecting the levels of specific transcription factors that act on the promoter. Our study is one of a few that links proteasome activity with transcription in mammalian cells and we suggest that this is achieved by regulation of transcription factor levels (Hattori et al., 2003; Lassot et al., 2007; Zhu et al., 2007; Bhat et al., 2008; Koues et al., 2008) . By using the Figure 7 Proteasome inhibition decreased astrogliosis in the rat brain. Rat brains were perfused with a microdialysis probe into the PFC or the striatum. The brains were isolated after 72h of perfusion starting <7 days after probe implantation. The probes were either left nonperfused or they were perfused with 250nM epoxomicin (n=7). Images presented here are all from a rat that was perfused for 72h with epoxomicin, starting 4 days after probe implantation into the PFC. Dotted lines indicate the area where the probe was located. The images are rotated for presentation purposes placing the midline below the probe. Results were comparable between all rats that were studied. (A) GFAP-IR showed astrogliosis around the area where the non-perfused microdialysis probe was located. Arrows indicate the area of astrogliosis around the probe site. (B) At higher magnification, the reactive GFAP positive astrocytic processes are clearly visible. (C) No astrogliosis was found around the epoxomicin-perfused probe and only little GFAP-IR is seen in several filaments and 'squiggles' (arrowheads). Cell layers further away from the probe looked normal. (D) At higher magnification no clear GFAP positive astrocytic processes are visible around the epoxomicin-perfused probe site. Only a punctate staining pattern is present, indicating the loss of GFAP cytoskeletal fibres. (E) Vimentin-IR also showed astrogliosis around the non-perfused probe site, similar to GFAP. An asterisk marks the area that looks normal, without astrogliosis. (F) Vimentin-IR was clearly decreased after epoxomicin-perfusion around the probe site, like GFAP. (G-H) S100β clearly stained astrocytes around the non-perfused (E) and epoxomicin-perfused (F) probe sites. (I-J) NeuN staining showed normal-looking neurons located around both the non-perfused (I) and the epoxomicin-perfused (J) probe site. Immediately adjacent to the probe site a NeuN-negative band was present in both conditions, as indicated by a dashes line. (K) Hsp70-IR was not detected around the non-perfused probe site. (L) Hsp70-IR was clearly upregulated around the epoxomicin-perfused site, indicating the area of the brain that was penetrated by epoxomicin. Scale bars indicate 100μm in (A, C, E-L) and 50μm in (B,D).
Genomatix webtool, potential transcription factors were revealed that could act on the promoters of different IF genes at the same time, which might occur during astrogliosis when GFAP, vimentin and nestin are upregulated. This analysis revealed 6 potential transcription factor families that cover in total 59 different transcription factors. Four of these transcription factors (CREB, c-JUN, EGR-1 and PAX6) were indeed found to be regulated by the proteasome, as was shown by the RT-PCR array (supplemental table 2). The most interesting transcription factor is EGR-1, which was strongly decreased upon proteasome inhibition (17-fold). This regulation by the proteasome corresponds to previous studies, which showed that EGR-1 can regulate the proteasome and vice versa (Bae et al., 2002; James et al., 2006; Fernandez et al., 2008) . Furthermore, various studies suggest a relationship between an increased EGR-1 expression with an increased GFAP expression (Mack et al., 1994; Desjardins et al., 1997) and a role in astrogliosis (Beck et al., 2008) . However, it needs to be emphasized that the promoter sequences contain many putative binding sites for a large number of transcription factors. Clearly, unraveling which transcription factors are involved in IF transcription in astrogliosis needs further investigation.
The significant downregulation of GFAP expression after proteasome inhibition was not in line with our expectations. In diseases where impaired proteasome activity is confirmed, GFAP protein levels are generally upregulated in reactive astrocytes (Tang et al., 2006) . The decrease in proteasome activity in AD described by others, however, was measured in whole brain homogenates (Keller et al., 2000; Lopez Salon M. et al., 2000; Glenn et al., 2004) , without discriminating between the different cell types present. Moreover, ubiquitin immunoreactivity was found mostly in inclusion bodies within neurons (Lowe et al., 1988; Mayer et al., 1996; Layfield et al., 2005) , but not in astrocytes. Therefore, it could be argued that in these diseases the proteasome is not inhibited in astrocytes, but might rather be activated. Tentatively, a more active proteasome in astrocytes may indicate that in AD these cells are trying to degrade Aβ, the main constituent of amyloid plaques in the brains of AD patients (Thal et al., 2000; Wyss-Coray et al., 2003; Pihlaja et al., 2008) . Evidence for this line of reasoning has to come from animal models with astrocyte-specific proteasome activity impairment. Moreover, our results put studies using systemic administration of proteasome inhibitors in a new perspective. For example it has been reported that systemic administration of epoxomicin in rats can induce a model of PD (McNaught et al., 2004) . Although attempts to replicate this model have not always been successful, no attention has gone out to astrocytes, which are likely to play a role in the disease process as well. In our opinion, it would be important to investigate neuron-specific proteasome inhibition in animal models to study the role of the UPS in neurodegenerative diseases.
The profound downregulation of the transcript levels of GFAP, vimentin and nestin by proteasome inhibitors offers a new approach to impede astrogliosis which may be beneficial for certain disease situations. Studies using GFAP-/-Vim-/-knockout mice (Pekny and Nilsson, 2005) , a model for reduced astrogliosis, show that reactive astrocytes are a main component in brain injury, stroke, neurodegeneration and the physiological aging of the brain. There is ongoing debate whether reactive gliosis is beneficial or detrimental to the surrounding neurons (Myer et al., 2006; Laird et al., 2008) . As it is increasingly recognized that astrocytes not only provide a general support to neurons, but are also essential for synaptic transmission and synchronizing neuronal signals, it may be that transition from quiescent astrocytes to reactive cells may affect their normal functional role and hence be damaging to neurons (Kang et al., 1998; Volterra and Meldolesi, 2005; Vesce et al., 2007) . In agreement with such a detrimental role, the hypertrophy of astrocytes was shown to coincide with cognitive decline, implying that reactive gliosis negatively influences cognition (Ingelsson et al., 2004; Kashon et al., 2004) . GFAP -/-Vim -/-mice and cultured astrocytes from these mice have shown that astrocytes without IF proteins show improved axonal sprouting and functional recovery after spinal cord injury (Menet et al., 2003) and improved synaptic regeneration in mice conducted with entorhinal cortex lesions (Wilhelmsson et al., 2004) . Furthermore, the retinal environment in GFAP-/-Vim-/-knockout mice was more permissive for retinal transplants compared to wildtype mice (Kinouchi et al., 2003) and in old GFAP-/-Vim-/-knockout mice cell proliferation and neurogenesis in the hippocampal dentate gyrus was increased (Larsson et al., 2004) . The beneficial effects of reactive gliosis appear to be limited to the acute phase of brain injury (Sofroniew, 2005; Li et al., 2008) .
Taken together, these findings indicate that inhibition of proteasomal activity may be a method to reduce astrogliosis, and could serve as a potential therapy in the future to treat CNS injuries. Our research proposes that novel CNS penetrant proteasome inhibitors could be considered as a treatment for astrogliosis particularly in conditions where gliosis prevents recovery of neuronal function. Notably, the proteasome inhibitor bortezomib has been registered for multiple myeloma treatment (San Miguel et al., 2008) as a first in-class drug and is currently also investigate in clinical trials as a potential candidate in the treatment of gliomas (Kubicek et al., 2008) . Because proteasome inhibitors could also cause negative effects in other cell types surrounding reactive astrocytes, it would be beneficial to study the mechanism behind IF protein regulation in greater detail to find more specific targets for the development of therapeutics. 
